Summary

Eligibility
for people ages 18-35 (full criteria)
Location
at Los Angeles, California and other locations
Dates
study started
completion around

Description

Summary

This is a clinical trial study that aims to evaluate the specificity of the relationship between reduced sensitivity to social reward and social anhedonia at both behavioral and neural levels. Individuals who recently experienced their first-episode psychosis will be recruited. Participants will be randomized 1:1 to motivational interviewing or a time- and format-matched control probe. At pre- and post-probe, participants will perform two social reward learning tasks in the scanner. With this design feature, we will examine the relationship between sensitivity to social reward and reduced subjective experience of social pleasure at both the behavioral and neural levels.

Official Title

Determining the Role of Social Reward Learning in Social Anhedonia in First-Episode Psychosis Using Motivational Interviewing in a Perturbation-Based Neuroimaging Approach

Keywords

Psychosis, social anhedonia, social reward learning, fMRI, sensitivity to reward, Anhedonia, Psychotic Disorders, Mental Disorders, Motivational Interviewing, Nutrition Didactic Training

Eligibility

You can join if…

Open to people ages 18-35

  • Age 18-35 years
  • A first episode of a psychotic illness that began within the past three years
  • Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 diagnosis of schizophrenia, schizophreniform, or schizoaffective disorder
  • Taking 2nd generation antipsychotic medications
  • Estimated premorbid IQ not less than 70 as assessed with the Wechsler Test of Adult Reading
  • Appropriate for scanning (i.e., no pacemaker or metal implants) and expressed willingness to participate in scanning
  • Sufficient fluency in English to comprehend testing procedures
  • Corrected vision of at least 20/30

You CAN'T join if...

  • No evidence that substance use makes the diagnosis ambiguous (rule out substance-induced psychosis)
  • No evidence of moderate or severe alcohol or substance use disorder in the past 3 months
  • No clinically significant disease based on medical history (e.g., epilepsy) or significant head injury
  • For females: no current pregnancy
  • No sedatives or anxiolytics on the day of assessment
  • No medication change 3 weeks prior to enrollment

Locations

  • University of California Los Angeles accepting new patients
    Los Angeles California 90095 United States
  • University of Alabama at Birmingham accepting new patients
    Birmingham Alabama 35294 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of Alabama at Birmingham
ID
NCT05617898
Study Type
Interventional
Participants
Expecting 152 study participants
Last Updated